Risk Assessment in Biopharmaceutical Development: Why It Should Never Be a One-Time Exercise
As a biopharmaceutical process advances toward commercialisation, the cost of uncertainty increases significantly. Every process parameter, raw material, and equipment decision can impact product quality, process robustness, and regulatory success — making continuous, staged risk assessment a strategic imperative.
Topic: Process Development · Risk Assessment (QbD)Level: AdvancedApplication: Biopharma, PPQ, CPP, CQA
In biopharmaceutical development, risk assessment is often treated as a regulatory checkpoint — something produced to satisfy a regulatory submission, filed, and then forgotten. This is a mistake. The most effective organisations treat risk assessment as a living, evolving knowledge management tool that is refined at every stage of process development. At Graphtal, we support a structured three-stage risk assessment methodology that ensures scientific rigour and regulatory confidence from process characterisation through to commercial manufacturing.
The Three Critical Stages of Risk Assessment
Risk assessment must be performed at minimum three times during late-stage biopharmaceutical process development. Each stage uses a different knowledge base, answers different questions, and produces a different set of outcomes. The framework is grounded in ICH Q9 (Quality Risk Management), ICH Q8 (Pharmaceutical Development), and the QbD principles that underpin modern regulatory expectations globally.
"In the middle of difficulty lies opportunity." — Each stage of risk reassessment is an opportunity to convert new process knowledge into better decisions, stronger controls, and a more defensible regulatory dossier.
1
Stage 1 — Before Process Characterization Studies
Prospective Risk Assessment — Structuring the Unknown
Before initiating Process Characterization (PC) studies, the objective is to systematically identify all potential risks that could affect Critical Quality Attributes (CQAs) and process performance. At this point, direct experimental data from characterisation studies does not yet exist — the assessment must draw on available prior knowledge to build a structured risk ranking that focuses experimental effort where it matters most.
Key Questions This Assessment Answers
Which process parameters are likely to be Critical Process Parameters (CPPs)?
Which material attributes require further investigation in DoE studies?
Where should experimental effort and resource be focused?
Which variables must be included in Design of Experiments (DoE) and at what ranges?
Knowledge Sources Used
Prior process development and laboratory data from earlier phases
Platform knowledge from similar molecules and unit operations
Historical manufacturing data from development-scale equipment
Published scientific literature and platform-specific mechanistic understanding
Outcome: A focused, efficient Process Characterization strategy — rather than attempting to test every possible variable, the risk assessment directs experimental effort to the highest-impact parameters and interactions. This directly reduces study cost and timeline.
2
Stage 2 — After Process Characterization Studies
Retrospective Refinement — Updating Based on Experimental Evidence
Once PC studies are completed, a significant body of new knowledge becomes available from DoE outputs, multivariate statistical models, response surface analyses, and interaction mapping. This is the ideal time to revisit and substantially update the original risk assessment — what was previously based on prior knowledge is now anchored in direct experimental evidence.
What the Updated Assessment Incorporates
Results from DoE studies — main effects, interactions, and curvature effects
Confirmed CPPs and definitively classified non-critical parameters
Proven Acceptable Ranges (PARs) and Normal Operating Ranges (NORs)
Parameter interactions and their cumulative impact on CQAs
Demonstrated process robustness and control strategy effectiveness
Scale-down model qualification data and TOST equivalence results
Outcome: An evidence-based updated risk profile that directly supports Design Space definition, regulatory submission dossier preparation (CTD Module 3), and process validation planning. Many initially high-risk parameters are reclassified as low-risk — this reclassification must be formally documented with the supporting DoE data.
3
Stage 3 — After Process Performance Qualification (PPQ)
Commercial-Scale Validation — Confirming Under Real Manufacturing Conditions
The final major risk review occurs after successful PPQ batches at commercial manufacturing scale. At this stage, theoretical understanding and scale-down model predictions are complemented — and tested — by actual commercial-scale manufacturing experience. Assumptions made during characterisation are now confirmed or challenged by real data from real equipment operated by real manufacturing teams.
What This Assessment Now Incorporates
PPQ batch performance data across all validated parameters
Manufacturing deviations encountered during PPQ and their root causes
Process trending data and control chart performance from PPQ batches
Continued Process Verification (CPV) early observations
Operator experience and equipment performance at commercial scale
Process capability indices (Cpk) for all critical and key parameters
Commercial manufacturing variability vs. scale-down model predictions
Outcome: Confirmation that the control strategy remains effective under routine manufacturing conditions. Identification of opportunities for continuous process improvement throughout the product lifecycle. Input to the Post-Approval Lifecycle Management (PALM) plan and the Continued Process Verification programme.
At a Glance — How Each Stage Differs
The three risk assessment stages share the same core methodology but differ fundamentally in their knowledge base, primary purpose, and regulatory output. Understanding this distinction prevents the common mistake of simply reusing the pre-characterisation assessment without meaningful update.
Dimension
Stage 1 Before PC Studies
Stage 2 After PC Studies
Stage 3 After PPQ
Knowledge Base
Prior knowledge, platform data, scientific literature
DoE results, multivariate models, scale-down model qualification
Risk Assessment Is a Cross-Functional Activity — Not Owned by Process Development Alone
One of the most common and consequential misconceptions in biopharmaceutical development is that risk assessment is owned and executed exclusively by process development scientists. In reality, the most valuable, comprehensive, and defensible risk assessments come from genuinely multidisciplinary teams where each function contributes a perspective that others cannot.
The Common Mistake
Risk assessment is treated as a process development deliverable — drafted by scientists, reviewed by QA for compliance, and submitted. Manufacturing, MSAT, QC, analytical, and regulatory perspectives are consulted inconsistently or added at the end without meaningful integration. The result is a document that looks complete but misses operationally critical risks.
The Graphtal Approach
Risk assessment is a cross-functional exercise conducted in structured workshops. Each discipline contributes at defined points in the assessment. Risks identified by manufacturing operations, analytical development, or supply chain that development scientists might overlook are formally integrated. The output is a document that reflects the full risk landscape — not just the scientific view.
Process Development (US/DS)
Process science, parameter–CQA relationships, mechanism of action of unit operations
MSAT
Bridges development and commercial production; scale-up risks and technology transfer considerations
Raw material variability, supplier risk, incoming material specifications, single-source dependencies
Subject Matter Experts (SMEs)
Specialist knowledge in specific unit operations, platform molecules, or regulatory jurisdictions
The consequence of single-function ownership: When manufacturing operations are not consulted, process parameters that are theoretically controllable in development may be practically difficult to control at commercial scale — and the risk assessment will not reflect this. When analytical development is excluded, limitations in assay sensitivity or precision may mean that a parameter's true impact on a CQA cannot be reliably detected — leading to false non-CPP classifications.
Risk Assessment as a Living Document — Continuous Evolution Throughout the Lifecycle
A risk assessment approved and filed at the time of BLA or MAA submission is not the end of the document — it is a snapshot of process knowledge at one point in time. As new information becomes available from every source of process knowledge, the risk assessment must be updated to remain current, accurate, and useful as a decision-making tool.
Triggers for Mandatory Risk Assessment Review
When must the risk assessment be updated?
Any significant new information that changes the risk profile of a parameter, material attribute, or unit operation should trigger a formal review and update of the risk assessment. This is not optional — it is required by ICH Q9 principles and expected by regulatory agencies as part of a robust Pharmaceutical Quality System under ICH Q10.
PC/PV Study Results
PPQ Data
CPV Observations
Manufacturing Deviations
OOS / OOT Investigations
Raw Material Changes
Facility or Equipment Changes
Regulatory Feedback
New Scientific Understanding
Technology Transfers
Regulatory alignment: This continuous approach aligns with the principles of Quality by Design (QbD) as described in ICH Q8(R2), Quality Risk Management under ICH Q9, Pharmaceutical Quality Systems under ICH Q10, and Lifecycle Management under ICH Q12. Health authorities increasingly expect to see evidence that risk assessments have been updated as process knowledge evolved — not simply presented as a static pre-characterisation exercise.
What Well-Executed Risk Assessment Enables
When performed rigorously at each of the three stages, with genuine cross-functional input, and continuously maintained as a living document, risk assessment delivers far more value than regulatory compliance. It becomes the strategic backbone of the entire process development and commercialisation programme.
Robust and Reliable Manufacturing Processes
By identifying and controlling the parameters that truly matter, the process is designed and validated around its real risk drivers — not a long list of parameters of equally uncertain importance. The result is a manufacturing process that performs consistently across sites, scales, and operators.
Effective, Science-Based Control Strategies
A risk assessment that accurately classifies CPPs and non-CPPs enables the control strategy to be proportionate — tight controls where they matter, and lighter oversight where the evidence shows it is safe to apply it. This prevents both under-control and over-control of the manufacturing process.
Reduced Process Variability
Understanding the root causes of process variability — before they manifest as OOS results, failed batches, or regulatory non-compliances — allows targeted interventions. Risk assessments that incorporate manufacturing experience identify variability sources that would not be visible from laboratory data alone.
Stronger Regulatory Confidence
A well-documented, staged risk assessment that clearly shows how scientific understanding evolved through the programme gives health authorities confidence that the applicant truly understands their process. This supports faster review timelines and reduces the risk of deficiency letters or inspection observations.
Successful Technology Transfer and Commercial Manufacturing
Risk assessments that incorporate MSAT and manufacturing perspectives are far more effective technology transfer tools than development-only documents. They explicitly identify the parameters and material attributes that require special attention during scale-up and site transfer — and document the evidence that controls are adequate.
Continuous Process Improvement Throughout the Lifecycle
A living risk assessment provides the scientific framework for evaluating post-approval changes. When a process improvement opportunity is identified — whether from commercial manufacturing experience or new scientific understanding — the risk assessment provides the basis for assessing impact and determining whether regulatory notification is required under ICH Q12.
How Graphtal Supports Structured Risk Assessment Programmes
Graphtal provides expert statistical consulting and data analytics support for biopharmaceutical organisations implementing structured, data-driven risk assessment methodologies across late-stage process development. Our team has deep experience applying Risk Ranking and Filtering (RRF), FMEA, and Impact Ratio frameworks across upstream and downstream unit operations for monoclonal antibodies, biosimilars, cell therapies, and other complex biologics.
Graphtal Services
Risk Assessment & Process Development Analytics Support
Ready to Build a Stronger Risk Assessment Programme?
Graphtal's process development statisticians support organisations from Phase 3 through to commercial launch — delivering data-driven risk assessments that regulators trust.
Our team of experienced professionals at Graphtal is ready to transform your project from idea to reality, ensuring alignment with your organisation goals through advanced data analytics and predictive modelling.
